GlassScriptPhysician profile
Hassan Kanj
NPI 1598815987
$108,854.95
in general payments reported to CMS, 2019-2025
53 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $26K · 2021: $8,238 · 2022: $21K · 2023: $9,951 · 2024: $2,088 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,374 · Food and Beverage: $2,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,374.25 |
| Food and Beverage | $2,767.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $63,792.78 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $28,306.45 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $5,643.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $1,892.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $1,088.46 | 2019-2025 | |
| Abbott Laboratories | $811.92 | 2019-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $694.42 | 2021-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $678.30 | 2019-2023 | Segluromet, Steglatro |
| Amneal Pharmaceuticals LLC | $628.89 | 2020-2023 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.23 | 2019-2023 | Jardiance |
| Abbvie INC. | $418.89 | 2019-2023 | |
| Lilly USA, LLC | $374.49 | 2020-2023 | Mounjaro, Jardiance |
| Corcept Therapeutics | $374.28 | 2020-2023 | Korlym |
| Mannkind Corporation | $270.91 | 2019-2022 | |
| Medtronic Minimed, INC. | $254.30 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Kanj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.